Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review

  • ID: 1290798
  • SWOT Analysis
  • 78 pages
  • GlobalData
  • Eli Lilly and Company
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Biogen Inc
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Pfizer Inc
  • MORE
Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, immune disorders, men's health and musculoskeletal problems. It also provides pet medicine, food-safety products and companion animal health products, besides services to the food animal industry. Lilly also has mid-to-late stage pipeline products. The company distributes human pharmaceutical and animal health products through independent wholesale distributors. It also promotes its products through sales representatives and marketing agreements with other pharmaceutical companies. The company offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co Key Recent Developments

Apr 24, 2018: Lilly Reports First-Quarter 2018 Financial Results
Apr 19, 2018: EBCC11 highlights by Europa Donna
Mar 09, 2018: Maura Dickler, M.D. To Become Vice President Of Late Phase Development At Lilly Oncology
Feb 06, 2018: Adocia Files Additional Arbitration Claims Against Eli Lilly & Company
Jan 31, 2018: Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Biogen Inc
  • F. Hoffmann-La Roche Ltd
  • Merck & Co Inc
  • Pfizer Inc
  • MORE
Section 1 - About the Company
  • Eli Lilly and Co - Key Facts
  • Eli Lilly and Co - Key Employees
  • Eli Lilly and Co - Key Employee Biographies
  • Eli Lilly and Co - Major Products and Services
  • Eli Lilly and Co - History
  • Eli Lilly and Co - Company Statement
  • Eli Lilly and Co - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Eli Lilly and Co - Business Description
  • Business Segment: Animal Health Products
  • Overview
  • Performance
  • Business Segment: Human Pharmaceutical Products
  • Overview
  • Performance
  • Geographical Segment: Europe
  • Performance
  • Geographical Segment: Japan
  • Performance
  • Geographical Segment: Other Foreign Countries
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Eli Lilly and Co - Corporate Strategy
  • Eli Lilly and Co - SWOT Analysis
  • SWOT Analysis - Overview
  • Eli Lilly and Co - Strengths
  • Eli Lilly and Co - Weaknesses
  • Eli Lilly and Co - Opportunities
  • Eli Lilly and Co - Threats
  • Eli Lilly and Co - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Eli Lilly and Co, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 24, 2018: Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance
  • Apr 19, 2018: EBCC11 highlights by Europa Donna
  • Mar 09, 2018: Maura Dickler, M.D. To Become Vice President Of Late Phase Development At Lilly Oncology
  • Feb 06, 2018: Adocia Files Additional Arbitration Claims Against Eli Lilly & Company
  • Jan 31, 2018: Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance
  • Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System
  • Dec 13, 2017: Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020
  • Dec 11, 2017: Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology
  • Dec 07, 2017: Gladstone Institutes Announces Research Collaboration With Lilly
  • Nov 21, 2017: Dexcom Announces Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Eli Lilly and Co, Key Facts
  • Eli Lilly and Co, Key Employees
  • Eli Lilly and Co, Key Employee Biographies
  • Eli Lilly and Co, Major Products and Services
  • Eli Lilly and Co, History
  • Eli Lilly and Co, Subsidiaries
  • Eli Lilly and Co, Joint Venture
  • Eli Lilly and Co, Key Competitors
  • Eli Lilly and Co, Ratios based on current share price
  • Eli Lilly and Co, Annual Ratios
  • Eli Lilly and Co, Annual Ratios
  • Eli Lilly and Co, Annual Ratios
  • Eli Lilly and Co, Interim Ratios
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Eli Lilly and Co, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Eli Lilly and Co, Performance Chart (2013-2017)
  • Eli Lilly and Co, Ratio Charts
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Sanofi
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Co
  • Biogen Inc
  • Baxter International Inc
  • AstraZeneca Plc
  • Amgen Inc
  • AbbVie Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll